Brigatinib: up next in our pipeline

An FDA breakthrough therapy under investigation in ALK+ NSCLC

LEARN MORE

A remarkable place doing remarkable work

We're looking for people who want to make a difference for cancer patients

OPEN POSITIONS

A unique, highly targeted approach to cancer

Our research & development program

LEARN MORE

NEWS & FEATURES

Latest News

5/24/16
ARIAD Announces Appointment of Jennifer L. Herron as Chief Commercial Officer
Read More
5/19/16
ARIAD Announces Pricing and Reimbursement for Iclusig in France
Read More

TWITTER FEED